



Novel Molecular Targets for Cardioprotection: The EU-CARDIOPROTECTION COST Action (CA16225)

Guest Editors:

Prof. Dr. Ioanna Andreadou

jandread@pharm.uoa.gr

Prof. Derek J Hausenloy

derek.hausenloy@duke-nus.edu.sg

Dr. Hector A. Cabrera Fuentes

Hector.A.Cabrera-Fuentes@biochemie.med.uni-giessen.de

Deadline for manuscript
submissions:

closed (1 April 2019)

Message from the Guest Editors

Dear Colleagues,

Novel molecular targets for cardioprotection need to be discovered in order to improve clinical outcomes of IHD patients. This is the overall objective of our newly established EU-CARDIOPROTECTION COST Action (CA16225 <http://www.cardioprotection.eu/>), which is dedicated to realising the therapeutic potential of novel cardioprotective therapies for patient benefit. This will be achieved through the discovery of novel therapeutic targets and strategies for cardioprotection (such as combination multi-targeted therapies), and investigating the confounding effects of co-morbidities and co-medication on cardioprotection. In this Special Issue of *IJMS*, we invite you to submit both review and original pre-clinical articles on the topic of cardioprotection with a special focus on novel molecular targets for cardioprotection.

- Mitochondria
- Reactive oxygen species
- Cytoprotective signaling pathways
- Cardioprotection
- Ischemia-Reperfusion injury
- Acute myocardial infarction
- Ischemic preconditioning
- Ischemic postconditioning
- Remote ischemic conditioning

